IOVS AJP: Regulatory, Integrative and Comparative Physiology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Detrick, B.
Right arrow Articles by Hooks, J. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Detrick, B.
Right arrow Articles by Hooks, J. J.
(Investigative Ophthalmology and Visual Science. 2001;42:163-169.)
© 2001 by The Association for Research in Vision and Ophthalmology, Inc.

Inhibition of Human Cytomegalovirus Replication in a Human Retinal Epithelial Cell Model by Antisense Oligonucleotides

Barbara Detrick1, Chandrasekharam N. Nagineni2, Lisa R. Grillone3, Kevin P. Anderson3, Scott P. Henry3 and John J. Hooks2

From 1 The Department of Pathology, The Johns Hopkins Medical Institutes, Baltimore, Maryland; 2 Immunology and Virology Section, Laboratory of Immunology, National Eye Institute, National Institutes of Health, Bethesda, Maryland; and 3 ISIS Pharmaceuticals, Carlsbad, California.

PURPOSE. The antiviral activity of first and second generation antisense oligonucleotides on human cytomegalovirus (CMV) replication was evaluated in two cell systems, the traditional system on human fibroblasts and on human retinal pigment epithelial (HRPE) cell culture system.

METHODS. To evaluate CMV replication strategies within the retina, an HRPE cell system permissive to CMV replication was developed. In this study, the antiviral activity of the antisense oligonucleotides, ISIS 2922 (Vitraven) and ISIS 13312, was evaluated in the traditional fibroblast antiviral assay and in the HRPE cell system. Antiviral activity was measured by evaluating inhibition of virus induced cytopathic effect, virus plaque formation, and virus gene expression.

RESULTS. Both oligonucleotides produced concentration-dependent inhibition of CMV cytopathic effect and CMV plaque formation in both human RPE cells and a human fibroblast cell line, MRC-5. The oligonucleotide, ISIS 2922, demonstrated a mean 50% inhibitory concentration (IC50) of 0.04 and 0.24 µM in HRPE and MRC-5 cells, respectively. The second-generation oligonucleotide, ISIS 13312, yielded similar results with IC50 levels of 0.05 and 0.3 µM in HRPE and MRC-5 cells, respectively. Similar findings were obtained with a CMV clinical isolate. In addition, initiation of effective oligonucleotide treatment could be introduced 6 days after CMV infection in HRPE cells, whereas, in the fibroblast cell line, oligonucleotide treatment was only effective up to 3 days after infection. Semiquantitative RT-PCR analysis demonstrated significant inhibition of CMV intermediate early and late mRNAs by both oligonucleotides.

CONCLUSIONS. These studies demonstrate that HRPE cells were significantly more sensitive than fibroblasts to the antiviral actions of ISIS 2922 and ISIS 13312. Moreover, the data indicate that the anti-CMV potency of the two oligonucleotides was similar. The enhanced potency of these oligonucleotides in HRPE cells may be associated with a delay in viral gene transcription and slow viral replication and spread in these cells.




This article has been cited by other articles:


Home page
 J. Immunol.Home page
J. J. Hooks, C. N. Nagineni, L. C. Hooper, K. Hayashi, and B. Detrick
IFN-{beta} Provides Immuno-Protection in the Retina by Inhibiting ICAM-1 and CXCL9 in Retinal Pigment Epithelial Cells
J. Immunol., March 15, 2008; 180(6): 3789 - 3796.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
C. Shi, A. R. Parker, L. Hua, C. N. Morrell, S. C. Lee, V. Bandaru, J. S. Dumler, T. C. Wu, and J. R. Eshleman
Anti-gene padlocks eliminate Escherichia coli based on their genotype
J. Antimicrob. Chemother., February 1, 2008; 61(2): 262 - 272.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
S. L. Williams-Aziz, C. B. Hartline, E. A. Harden, S. L. Daily, M. N. Prichard, N. L. Kushner, J. R. Beadle, W. B. Wan, K. Y. Hostetler, and E. R. Kern
Comparative Activities of Lipid Esters of Cidofovir and Cyclic Cidofovir against Replication of Herpesviruses In Vitro
Antimicrob. Agents Chemother., September 1, 2005; 49(9): 3724 - 3733.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
M. Michaelis, T. Suhan, A. Reinisch, A. Reisenauer, C. Fleckenstein, D. Eikel, H. Gumbel, H. W. Doerr, H. Nau, and J. Cinatl Jr
Increased Replication of Human Cytomegalovirus in Retinal Pigment Epithelial Cells by Valproic Acid Depends on Histone Deacetylase Inhibition
Invest. Ophthalmol. Vis. Sci., September 1, 2005; 46(9): 3451 - 3457.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
Y. Momma, C. N. Nagineni, M. S. Chin, K. Srinivasan, B. Detrick, and J. J. Hooks
Differential Expression of Chemokines by Human Retinal Pigment Epithelial Cells Infected with Cytomegalovirus
Invest. Ophthalmol. Vis. Sci., May 1, 2003; 44(5): 2026 - 2033.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
S. P. Henry, R. C. Miner, W. L. Drew, J. Fitchett, C. York-Defalco, L. M. Rapp, and A. A. Levin
Antiviral Activity and Ocular Kinetics of Antisense Oligonucleotides Designed to Inhibit CMV Replication
Invest. Ophthalmol. Vis. Sci., October 1, 2001; 42(11): 2646 - 2651.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2001 by the Association for Research in Vision and Ophthalmology